NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Receives Average Recommendation of “Moderate Buy” from Analysts

Shares of NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) have earned a consensus recommendation of “Moderate Buy” from the twelve research firms that are presently covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, nine have given a buy recommendation and one has issued a strong buy recommendation on the company. The average twelve-month price target among brokerages that have covered the stock in the last year is $47.00.

A number of research firms have recently issued reports on NAMS. Leerink Partners restated an “outperform” rating and issued a $55.00 target price on shares of NewAmsterdam Pharma in a report on Tuesday, January 6th. Royal Bank Of Canada increased their price objective on NewAmsterdam Pharma from $44.00 to $47.00 and gave the stock an “outperform” rating in a research note on Wednesday, January 21st. Weiss Ratings restated a “sell (d-)” rating on shares of NewAmsterdam Pharma in a research report on Thursday, January 22nd. Wall Street Zen cut NewAmsterdam Pharma from a “hold” rating to a “sell” rating in a research note on Saturday. Finally, Guggenheim increased their price target on shares of NewAmsterdam Pharma from $41.00 to $45.00 and gave the stock a “buy” rating in a research report on Thursday.

NewAmsterdam Pharma Stock Up 1.7%

NASDAQ:NAMS opened at $36.17 on Tuesday. NewAmsterdam Pharma has a 1-year low of $14.06 and a 1-year high of $42.00. The stock has a fifty day simple moving average of $33.98 and a 200 day simple moving average of $32.78. The firm has a market capitalization of $4.10 billion, a price-to-earnings ratio of -20.91 and a beta of 0.06.

NewAmsterdam Pharma (NASDAQ:NAMS) last released its quarterly earnings results on Wednesday, February 18th. The company reported ($0.63) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.40) by ($0.23). NewAmsterdam Pharma had a negative net margin of 906.22% and a negative return on equity of 26.67%. The firm had revenue of $0.03 million for the quarter, compared to analyst estimates of $0.92 million. Equities analysts predict that NewAmsterdam Pharma will post -1.75 earnings per share for the current year.

Insider Activity at NewAmsterdam Pharma

In other NewAmsterdam Pharma news, insider Johannes Jacob Piete Kastelein sold 6,000 shares of NewAmsterdam Pharma stock in a transaction on Monday, January 5th. The shares were sold at an average price of $33.25, for a total transaction of $199,500.00. Following the completion of the sale, the insider owned 73,481 shares of the company’s stock, valued at $2,443,243.25. This trade represents a 7.55% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CAO Louise Frederika Kooij sold 75,117 shares of the business’s stock in a transaction on Tuesday, December 23rd. The shares were sold at an average price of $36.21, for a total transaction of $2,719,986.57. Following the transaction, the chief accounting officer owned 15,000 shares in the company, valued at approximately $543,150. This represents a 83.35% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders sold 298,647 shares of company stock worth $10,236,050. Company insiders own 20.84% of the company’s stock.

Institutional Investors Weigh In On NewAmsterdam Pharma

A number of hedge funds and other institutional investors have recently made changes to their positions in NAMS. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new stake in shares of NewAmsterdam Pharma during the 1st quarter valued at about $610,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its position in NewAmsterdam Pharma by 13.6% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 288,134 shares of the company’s stock valued at $5,898,000 after acquiring an additional 34,563 shares in the last quarter. Teacher Retirement System of Texas acquired a new stake in NewAmsterdam Pharma in the second quarter valued at approximately $212,000. Bank of New York Mellon Corp acquired a new stake in NewAmsterdam Pharma in the second quarter valued at approximately $6,392,000. Finally, Geode Capital Management LLC grew its position in NewAmsterdam Pharma by 15.9% in the second quarter. Geode Capital Management LLC now owns 99,457 shares of the company’s stock worth $1,800,000 after acquiring an additional 13,629 shares in the last quarter. 89.89% of the stock is owned by hedge funds and other institutional investors.

NewAmsterdam Pharma Company Profile

NewAmsterdam Pharma, Inc is a clinical‐stage biopharmaceutical company focused on discovering and developing novel small‐molecule therapies for cardiometabolic diseases. The company’s research efforts are aimed at addressing key unmet needs in metabolic syndrome, obesity and type 2 diabetes by modulating pathways involved in glucose regulation, energy homeostasis and lipid metabolism.

The company’s development pipeline features multiple small‐molecule candidates at various stages of preclinical and clinical evaluation.